Sales of over-the-counter products aimed at easing the side effects of weight-loss medications have seen a boost for Haleon, the company behind Advil, TUMS, and Biotène. In the U.S., Haleon has partnered with major retailers like CVS Pharmacy to display its products in specialized sections dedicated to GLP-1 weight-loss drugs, in addition to traditional store aisles. This strategy has reportedly led to a 24% increase in sales per store, according to a company spokesperson. The growth was observed during the first quarter of the year, and Haleon claims it controls the majority of GLP-1-related shelf space at CVS. GLP-1, or glucagon-like peptide-1, is a hormone that helps regulate appetite and blood sugar levels. Weight-loss medications such as Wegovy (from Novo Nordisk), Zepbound (from Eli Lilly), and Foundayo mimic this hormone to help people feel fuller, leading to reduced food intake. However, these drugs are associated with side effects such as nausea, vomiting, diarrhea, and abdominal pain, which have led to increased demand for products that can help manage these symptoms. CVS Pharmacy has responded to this trend by expanding its product selection to include both its own brand and national brands of over-the-counter items that help manage the side effects of GLP-1 medications. In a statement, the pharmacy chain emphasized its efforts to make it easier for customers to manage these side effects, though it did not directly address Haleon’s strategy or its success in increasing sales. Haleon is also exploring similar strategies with other major retailers, including Walmart and Target, according to the company’s spokesperson. However, no details were provided on the progress or results of these discussions. With GLP-1 medications currently used by approximately 11% of the U.S. population, the demand for complementary products is likely to continue growing as more people seek support in managing the side effects of these popular weight-loss treatments.